

Amendments to the Claims

Please cancel claims 2-3 and 12-13 without prejudice or disclaimer, and amend the claims as listed below.

The listing of claim will replace all prior versions and listings of claims in the application:

Listing of claims:

Claim 1. (currently amended) Isolated An isolated human DCR5 protein, having the amino acid sequence as set forth in SEQ ID NO: 12.

Claim 2-3. Canceled

4. (currently amended) An isolated antibody which specifically binds the isolated human DCR5 protein of claim 1.

5. (original) The antibody of claim 4, which is a monoclonal antibody.

6. (original) A composition comprising the human DCR5 protein of claim 1, in a pharmaceutically acceptable carrier.

7. (original) A composition comprising the antibody of claim 4, in a pharmaceutically acceptable carrier.

8. (original) A human DCR5 protein produced by the method of:

- a) constructing a vector comprising a nucleic acid molecule containing a nucleotide sequence encoding human DCR5 protein as set forth in SEQ ID NO: 12, wherein the nucleic acid molecule is operatively linked to an expression control sequence capable of directing its expression in a host cell;
- b) introducing the vector of (a) into a host cell;

c) growing the host cell of (b) under conditions which permit the production of human DCR5 protein; and

d) recovering the human DCR5 protein so produced.

9. (currently amended) The protein of claim [7] 8, wherein the host cell is a bacterial, yeast, insect or mammalian cell.

10. (original) The human DCR5 protein of claim 1, fused to an immunoglobulin constant region.

11. (original) The human DCR5 protein of claim 10, wherein the immunoglobulin constant region is the Fc portion of human IgG1.

Claims 12-13. Canceled